Multiple Sclerosis (MS) is a condition in which the body’s own immune system mistakenly attacks the protective covering of nerve fibers, causing problems such as muscle weakness, vision changes, and fatigue. In the relapsing form of the disease, symptoms can improve and then return again. The study uses oral tablets called MAVENCLAD that contain the active ingredient cladribine, which works by reducing the activity of certain immune cells that are involved in the disease.
The purpose of the study is to see how the drug changes the communication points between immune cells, known as the immune synapse, after one year of treatment compared with people who do not have the disease. Participants will take the tablets as directed for up to a year and will attend regular visits where blood samples are collected and simple tests are performed, such as a walk test, a hand‑function test, and a disability rating called the EDSS (a scale that measures how MS affects daily activities). At the start and after six and twelve months, brain scans using MRI will be done to look for changes in lesions, and the results will be compared with baseline measurements.
Greece 
